Methsuximide
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318204

CAS#: 77-41-8

Description: Mesuximide is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin and Celontin. The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.


Chemical Structure

img
Methsuximide
CAS# 77-41-8

Theoretical Analysis

MedKoo Cat#: 318204
Name: Methsuximide
CAS#: 77-41-8
Chemical Formula: C12H13NO2
Exact Mass: 203.09
Molecular Weight: 203.241
Elemental Analysis: C, 70.92; H, 6.45; N, 6.89; O, 15.74

Price and Availability

Size Price Availability Quantity
25mg USD 300 2 weeks
100mg USD 660 2 weeks
Bulk inquiry

Synonym: Methsuximide; Mesuximide; Celontin; Petinutin; Mesuximidum; Methsuximid; (±)-Mesuximide; N,2-dimethyl-2-Phenylsuccinimide; PM 396

IUPAC/Chemical Name: 1,3-dimethyl-3-phenylpyrrolidine-2,5-dione

InChi Key: AJXPJJZHWIXJCJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3

SMILES Code: O=C(C(C1=CC=CC=C1)(C)C2)N(C)C2=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Biological target: Methsuximide is an anticonvulsant agent.
In vitro activity: TBD
In vivo activity: TBD

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMF 25.0 123.01
DMSO 30.0 147.61
DMSO:PBS (pH 7.2) (1:40) 0.0 0.10
Ethanol 25.0 123.01

Preparing Stock Solutions

The following data is based on the product molecular weight 203.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: TBD
In vitro protocol: TBD
In vivo protocol: TBD

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Sigler M, Strassburg HM, Boenigk HE. Effective and safe but forgotten:
methsuximide in intractable epilepsies in childhood. Seizure. 2001
Mar;10(2):120-4. PubMed PMID: 11407955.


2: Blakely E, Starin S, Poling A. Effects of mephenytoin and methsuximide on the
reaction time of pigeons. Pharmacol Biochem Behav. 1988 Dec;31(4):787-90. PubMed
PMID: 3252269.


3: Schlinger H, Wilkenfield J, Poling A. Effects of methsuximide and mephenytoin
on the responding of pigeons under a fixed-consecutive-number schedule with and
without an external discriminative stimulus. Psychopharmacology (Berl).
1988;95(2):216-21. PubMed PMID: 3137600.


4: Schlinger H, Poling A. Acute and chronic effects of methsuximide and
mephenytoin on the delayed-matching-to-sample performance of pigeons.
Psychopharmacology (Berl). 1988;95(1):82-6. PubMed PMID: 3133702.


5: Sklenovský A, Chmela Z. The effect of antiepileptic drugs. II. (Valproate,
methsuximide) on nonesterified fatty acids in the brain structures during
convulsive state. Acta Univ Palacki Olomuc Fac Med. 1987;117:125-35. PubMed PMID:
2963488.


6: Browne TR, Feldman RG, Buchanan RA, Allen NC, Fawcett-Vickers L, Szabo GK,
Mattson GF, Norman SE, Greenblatt DJ. Methsuximide for complex partial seizures:
efficacy, toxicity, clinical pharmacology, and drug interactions. Neurology. 1983
Apr;33(4):414-8. PubMed PMID: 6403891.


7: Strong JM, Abe T, Gibbs EL, Atkinson AJ Jr. Plasma levels of methsuximide and
N-desmethylmethsuximide during methsuximide therapy. Neurology. 1974
Mar;24(3):250-5. PubMed PMID: 4855951.


8: Horning MG, Butler C, Harvey DJ, Hill RM, Zion TE. Metabolism of
N,2-dimethyl-2-phenylsuccinimide (methsuximide) by the epoxide-diol pathway in
rat, guinea pig and human. Res Commun Chem Pathol Pharmacol. 1973
Sep;6(2):565-78. PubMed PMID: 4750102.


9: Karch SB. Methsuximide overdose. Delayed onset of profound coma. JAMA. 1973
Mar 26;223(13):1463-5. PubMed PMID: 4740029.


10: Orton TC, Nicholls PJ. Effect in rats of subacute administration of
ethosuximide, methsuximide and phensuximide on hepatic microsomal enzymes and
porphyrin turnover. Biochem Pharmacol. 1972 Aug 15;21(16):2253-61. PubMed PMID:
4646191.


11: Orton TC, Nicholls PJ. Porphyrogenic activity of methsuximide and its
demethylated metabolite. J Pharm Pharmacol. 1972 Feb;24(2):151-2. PubMed PMID:
4401970.


12: STEIN S, PEMBROOK RC. CROSS-SENSITIVITY TO DILANTIN (DIPHENYLBYDANTOIN) AND
CELONTIN (METHSUXIMIDE). J Pediatr. 1965 Apr;66:799-801. PubMed PMID: 14271375.


13: CHEN G, WESTON JK, BRATTON AC Jr. Anticonvulsant activity and toxicity of
phensuximide, methsuximide and ethosuximide. Epilepsia. 1963 Mar;4:66-76. PubMed
PMID: 14020499.


14: Besag FM, Berry DJ, Vasey M. Methsuximide reduces valproic acid serum levels.
Ther Drug Monit. 2001 Dec;23(6):694-7. PubMed PMID: 11802106.


15: Besag FM, Berry DJ, Pool F. Methsuximide lowers lamotrigine blood levels: A
pharmacokinetic antiepileptic drug interaction. Epilepsia. 2000 May;41(5):624-7.
PubMed PMID: 10802770.


16: Wad N, Bourgeois B, Krämer G. Serum protein binding of
desmethyl-methsuximide. Clin Neuropharmacol. 1999 Jul-Aug;22(4):239-40. PubMed
PMID: 10442255.


17: May TW, Rambeck B, Jürgens U. Influence of oxcarbazepine and methsuximide on
lamotrigine concentrations in epileptic patients with and without valproic acid
comedication: results of a retrospective study. Ther Drug Monit. 1999
Apr;21(2):175-81. PubMed PMID: 10217337.


18: Hurst DL. Methsuximide therapy of juvenile myoclonic epilepsy. Seizure. 1996
Mar;5(1):47-50. PubMed PMID: 8777552.


19: Dooley J, Camfield P, Buckley D, Gordon K, Wirrell E, Camfield C.
Methsuximide-induced movement disorder. Pediatrics. 1991 Dec;88(6):1291-2. PubMed
PMID: 1956755.


20: Tennison MB, Greenwood RS, Miles MV. Methsuximide for intractable childhood
seizures. Pediatrics. 1991 Feb;87(2):186-9. PubMed PMID: 1987529.